Antifungal susceptibility testing practices at acute care hospitals enrolled in the national healthcare safety network, United States, 2011-2015

Open Forum Infectious Diseases

Volumn 4, Issue 4, 2017, Pages

  Vallabhaneni, Snigdha ^a   Sapiano, Mathew ^b   Weiner, Lindsey M ^b   Lockhart, Shawn R ^a   Magill, Shelley ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Antifungal agents; Antifungal susceptibility testing; Candidemia; Laboratory practices; Resistance

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; BROTH DILUTION; EMERGENCY CARE; FUNGUS ISOLATION; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES;

EID: 85032856644     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofx175     Document Type: Article

References (12)

1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198-208.
2. Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis. 2012;55:1352-61.
3. Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One. 2015;10:e0120452.
4. Vallabhaneni S, Cleveland AA, Farley MM, et al. Epidemiology and risk factors for Echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based Candidemia Surveillance Program, 2008-2014. Open Forum Infect Dis. 2015;2:ofv163.
5. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-50.
6. Vallabhaneni S, Kallen A, Tsay S, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus- United States, May 2013-August 2016. MMWR Morb Mortal Wkly Rep. 2016;65:1234-7.
7. Shah DN, Yau R, Weston J, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66:2146-51.
8. Pai MP, Pendland SL. Antifungal susceptibility testing in teaching hospitals. Ann Pharmacother. 2003;37:192-6.
9. CfDCaP (CDC). Patient safety component-annual hospital survey. Available at: https://www.cdc.gov/nhsn/forms/57.103_pshospsurv_blank.pdf. Accessed 10 April 2017.
10. CfDCaP (CDC). Bloodstream infection event (central line-associated bloodstream infection and non-central line-associated bloodstream infection). Available at: https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf. Accessed 10 April 2017.
11. Tsay S, Welsh RM, Adams EH, et al. Notes from the field: ongoing transmission of Candida auris in health care facilities-United States, June 2016-May 2017. MMWR Morb Mortal Wkly Rep. 2017;66:514-5.
12. Wiederhold NP, Gil VG, Gutierrez F, et al. First detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in Aspergillus fumigatus isolates in the United States. J Clin Microbiol. 2016;54:168-71.